A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

PHASE3CompletedINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

April 30, 2019

Study Completion Date

June 30, 2019

Conditions
Epilepsy
Interventions
DRUG

Lacosamide Tablet

"* Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"

DRUG

Lasosamide Oral Solution

"* Active Substance: Lacosamide~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use"

OTHER

Placebo Tablet

"* Active Substance: Placebo~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"

OTHER

Placebo Oral Solution

"* Active Substance: Placebo~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use"

Trial Locations (115)

10016

Sp0982 043, New York

20603

Sp0982 010, Waldorf

20817

Sp0982 007, Bethesda

32224

Sp0982 011, Jacksonville

32405

Sp0982 013, Panama City

33470

Sp0982 042, Wellington

33952

Sp0982 002, Port Charlotte

35007

Sp0982 028, Alabaster

53715

Sp0982 023, Madison

55422

Sp0982 025, Golden Valley

61637

Sp0982 021, Peoria

62702

Sp0982 045, Springfield

63131

Sp0982 029, St Louis

70121

Sp0982 009, New Orleans

72205

Sp0982 005, Little Rock

75401

Sp0982 050, Greenville

77025

Sp0982 034, Houston

78207

Sp0982 047, San Antonio

78229

Sp0982 038, San Antonio

78758

Sp0982 053, Austin

80202

Sp0982 035, Denver

80910

Sp0982 031, Colorado Springs

83702

Sp0982 015, Boise

90404

Sp0982 008, Santa Monica

92868

Sp0982 018, Irvine

98057

Sp0982 027, Renton

06810

Sp0982 036, Danbury

Unknown

Sp0982 981, Parkville

Sp0982 980, Chatswood

Sp0982 985, Heidelberg

Sp0982 986, Parkville

Sp0982 201, Brussels

Sp0982 202, Ghent

Sp0982 200, Leuven

Sp0982 181, Curitiba

Sp0982 180, Florianópolis

Sp0982 186, Passo Fundo

Sp0982 185, Porto Alegre

Sp0982 188, Rio de Janeiro

Sp0982 183, São Paulo

Sp0982 184, São Paulo

Sp0982 500, Blagoevgrad

Sp0982 501, Sofia

Sp0982 971, Beijing

Sp0982 976, Changchun

Sp0982 975, Chongqing

Sp0982 097, Fuzhou

Sp0982 973, Hangzhou

Sp0982 972, Shanghai

Sp0982 550, Ostrava Poruba

Sp0982 553, Prague

Sp0982 556, Prague

Sp0982 552, Zlín

Sp0982 255, Bron

Sp0982 252, Lille

Sp0982 251, Nancy

Sp0982 250, Rennes

Sp0982 305, Berlin

Sp0982 303, Erlangen

Sp0982 314, Freiburg im Breisgau

Sp0982 311, Marburg

Sp0982 302, München

Sp0982 600, Budapest

Sp0982 603, Szeged

Sp0982 850, Rehovot

Sp0982 851, Tel Litwinsky

Sp0982 351, Torino

Sp0982 907, Asaka

Sp0982 906, Fukuoka

Sp0982 910, Gifu

Sp0982 903, Hamamatsu

Sp0982 902, Hiroshima

Sp0982 913, Itami

Sp0982 912, Kagoshima

Sp0982 914, Kodaira

Sp0982 909, Kokubunji

Sp0982 901, Niigata

Sp0982 911, Ōmura

Sp0982 900, Sapporo

Sp0982 908, Shinjuku-Ku

Sp0982 904, Shizuoka

Sp0982 161, Guadalajara

Sp0982 657, Częstochowa

Sp0982 655, Gdansk

Sp0982 658, Gdynia

Sp0982 652, Gliwice

Sp0982 651, Katowice

Sp0982 653, Katowice

Sp0982 654, Katowice

Sp0982 656, Tyniec Mały

Sp0982 650, Warsaw

Sp0982 659, Warsaw

Sp0982 451, Lisbon

Sp0982 704, Iași

Sp0982 707, Iași

Sp0982 700, Timișoara

Sp0982 750, Kazan'

Sp0982 758, Pyatigorsk

Sp0982 755, Saint Petersburg

Sp0982 756, Saint Petersburg

Sp0982 752, Samara

Sp0982 753, Smolensk

Sp0982 757, Yekaterinburg

Sp0982 821, Bardejov

Sp0982 823, Hlohovec

Sp0982 940, Daegu

Sp0982 941, Seoul

Sp0982 944, Seoul

Sp0982 402, Barcelona

Sp0982 406, Córdoba

Sp0982 407, Madrid

Sp0982 404, Málaga

Sp0982 403, Seville

Sp0982 961, Taichung

Sp0982 960, Taipei

Sponsors
All Listed Sponsors
collaborator

Pharmaceutical Research Associates

OTHER

lead

UCB BIOSCIENCES, Inc.

INDUSTRY